BDX - Becton Dickinson Non-GAAP EPS of $3.18 beats by $0.23 revenue of $5.01B beats by $230M; updates FY22 guidance

Becton, Dickinson press release (NYSE:BDX): Q2 Non-GAAP EPS of $3.18 beats by $0.23. Revenue of $5.01B (+2.0% Y/Y) beats by $230M. On a pre-spin basis, which includes the results of the Diabetes Care business: The company now expects fiscal year 2022 revenues to be in the range of approximately $19.6 billion to $19.8 billion (consensus of $19.09B), which reflects an increase of approximately $50 million at the mid-point compared to $19.55 billion to $19.75 billion previously announced. The company now expects fiscal year 2022 adjusted diluted EPS to be $12.85 to $13.00 (consensus of $12.18), which reflects an increase of 2.5 cents at the mid-point, including an operational increase of 7.5 cents offset by an incremental headwind of approximately 5 cents from foreign currency, compared to $12.80 to $13.00 previously. On a post-spin basis which reflects the former Diabetes Care business as discontinued operations in both the current and prior-year periods,

For further details see:

Becton, Dickinson Non-GAAP EPS of $3.18 beats by $0.23, revenue of $5.01B beats by $230M; updates FY22 guidance